Kidney effects of Glucagon-Like Peptide 1 (GLP1): from molecular foundations to a pharmacophysiological perspective
Authors:
- Jorge Rico-FontalvoJorge Rico-Fontalvo
- Maricely ReinaMRMaricely Reina
- María José SolerMSMaría José Soler
- Mario Unigarro-PalaciosMUMario Unigarro-Palacios
- Juan Pablo Castañeda-GonzálezJCJuan Pablo Castañeda-González
- Javier Jiménez QuinteroJQJavier Jiménez Quintero
- María Raad-SarabiaMRMaría Raad-Sarabia
- Thyago Proença de MoraesTMThyago Proença de Moraes
- Rodrigo Daza-ArnedoRDRodrigo Daza-Arnedo
Open Access
- 1 December 2024
- journal article
- review article
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 46 (4) , e20240101
Abstract
GLP1 receptor agonists (GLP1-RAs) are drugs that mimic the effects of the incretin hormone GLP1 and were initially introduced in medicine for the treatment of diabetes in 2005 and for obesity in 2014. Over time, data from secondary and exploratory objectives of large randomized controlled-trials suggested that GLP1-RAs could also exert renal action by slowing the progression of kidney disease in patients with and without diabetes. Based on this rationale, the Flow study (1 mg semaglutide vs placebo) was designed and recruitment began in 2019 until May 2021. The recently published results confirmed the effect of semaglutide in reducing the composite renal outcome. However, similar to SGLT2 inhibitors, the potential mechanisms behind the renal effects of GLP1-RAs still need to be elucidated. The aim of this review is to address the different physiological mechanisms of GLP1-RAs at the renal level, using evidence from experimental studies and current scientific literature.Keywords
This publication has 48 references indexed in Scilit:
- The Weight-loss Effect of GLP-1RAs Glucagon-Like Peptide-1 Receptor Agonists in Non-diabetic Individuals with Overweight or Obesity: A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Randomized Controlled TrialsThe American Journal of Clinical Nutrition, 2023
- Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or ObesityJAMA, 2021
- Glucagon-like peptide 1 (GLP-1)Molecular Metabolism, 2019
- GLP-1: Molecular mechanisms and outcomes of a complex signaling systemNeurochemistry International, 2019
- Glucagon-like peptide-1 receptor action in the vasculaturePeptides, 2019
- Glucagon‐like peptide‐1 receptor agonists in type 2 diabetes treatment: are they all the same?Diabetes/Metabolism Research and Reviews, 2018
- GLP-1 receptor agonists show neuroprotective effects in animal models of diabetesPeptides, 2018
- Glucagon-like Peptide-1 Receptor Agonist Liraglutide Inhibits Endothelin-1 in Endothelial Cell by Repressing Nuclear Factor-Kappa B ActivationCardiovascular Drugs and Therapy, 2013
- Glucagon-like peptide-1 inhibits angiotensin II-induced mesangial cell damage via protein kinase AMicrovascular Research, 2012
- Structure-activity studies of glucagon-like peptide-1.Journal of Biological Chemistry, 1994